# Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

Source: https://onco.cc/trials/nct01829711/  
OnCo record `nct01829711` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Moxetumomab pasudotox in Leukaemia, run by MedImmune LLC, completed.

## Summary

Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia is a phase 3 interventional study registered as NCT01829711 by MedImmune LLC, with 80 participants recorded, started 2013-04-29 and reaching its primary completion in 2017-05-24. Interventions recorded: Moxetumomab pasudotox, IV Bag Protectant for Moxetumomab pasudotox. Conditions recorded: Leukemia, Hairy Cell.

Linked to the drug Moxetumomab pasudotox because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01829711
- Phase: 3
- Setting: A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia
- Sponsor: MedImmune LLC
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT01829711: https://clinicaltrials.gov/study/NCT01829711

## Connected records

- cancers: [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/)
- drugs: [Moxetumomab pasudotox](https://onco.cc/drugs/moxetumomab-pasudotox/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct01829711.json